Esperion Therapeutics Inc. (ESPR)
Esperion Therapeutics, Inc. (ESPR) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health Transcript
Esperion Therapeutics, Inc. ( ESPR ) Discusses Breaking the Statin Intolerance Barrier and Closing the Care Gap in Cardiovascular Health November 11, 2025 2:00 PM EST Company Participants Sheldon Koenig - President, CEO & Director LeAnne Bloedon Conference Call Participants Dharmesh Patel Fatima Rodriguez Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Jason Zemansky - BofA Securities, Research Division Rick Miller - Cantor Fitzgerald & Co., Research Division Presentation Operator Good day, everyone.
ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
Esperion Therapeutics, Inc. (ESPR) Q3 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. ( ESPR ) Q3 2025 Earnings Call November 6, 2025 8:00 AM EST Company Participants Alina Venezia Sheldon Koenig - President, CEO & Director Benjamin Halladay - Chief Financial Officer Lisa Schafer Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Kristen Kluska - Cantor Fitzgerald & Co., Research Division Kyuwon Choi - Goldman Sachs Group, Inc., Research Division Serge Belanger - Needham & Company, LLC, Research Division Sara Nik - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Hello, ladies and gentlemen, and thank you for standing by.
Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to a loss of $0.15 per share a year ago.
ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
ESPR Stock Drops 17% on Pricing of $75M Common Stock Offering
Esperion's stock sinks after pricing its common stock offering at $2.50 per share, a 19% discount to the prior close.
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises
Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.
Esperion Therapeutics, Inc. (ESPR) Q2 2025 Earnings Call Transcript
Esperion Therapeutics, Inc. (NASDAQ:ESPR ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants Alina Venezia - Corporate Participant Benjamin Halladay - Chief Financial Officer Betty Jean Swartz - Chief Business Officer Lisa Schafer - Corporate Participant Sheldon L. Koenig - President, CEO & Director Conference Call Participants Georgia Bank - Jefferies LLC, Research Division Jason Eron Zemansky - BofA Securities, Research Division Jessica Macomber Fye - JPMorgan Chase & Co, Research Division Joseph Pantginis - H.C.
Esperion Therapeutics (ESPR) Reports Q2 Loss, Tops Revenue Estimates
Esperion Therapeutics (ESPR) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to a loss of $0.05 per share a year ago.
Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for
Esperion Therapeutics (ESPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can The Promise Of Profitability And Pipelines Sustain A Recovery For Esperion Therapeutics?
Esperion's recent rebound is driven by stronger-than-expected prescription growth, revived business momentum after Medicare coverage issues subsided, and good news flow from investor conferences. Management projects profitability by Q1 2026, but I am wary given current revenue, cash, and expense guidance—profitability claims seem optimistic without a clear revenue boost. Pipeline developments, including a triple-combo LDL-C pill and liver/kidney therapies, could be transformative, but near-term catalysts hinge on execution and proof of profitability.
